Shilpa Medicare Q2 FY27: PAT +80% YoY to ₹79 Cr, revenue +43%, op margin slips 240bps
PAT +79.67% YoY · revenue +42.96% · margins compressing
₹529.12 Cr
+42.96% YoY
₹79.18 Cr
+79.67% YoY
14.72%
+2.9pp YoY
₹4.05
Consolidated revenue from operations rose 43.0% YoY to ₹529.12 Cr (₹370.12 Cr a year ago) and consolidated PAT rose 79.7% YoY to ₹79.18 Cr (₹44.07 Cr) in Q2 FY27, taking basic EPS to ₹4.05 from ₹2.25. Sequentially, revenue grew 13.6% from ₹465.78 Cr but PAT fell 21.5% from ₹100.88 Cr — this QoQ drop is a tax-base artefact, not an operating one: the June quarter had booked a one-time ₹26.8 Cr deferred-tax liability reversal (new income-tax regime adoption) that pushed its effective tax rate negative; absent that one-off, underlying PBT actually rose 5.6% QoQ to ₹103.53 Cr from ₹98.06 Cr.
Q2 FY-2027 vs prior quarters
Operating margin (EBITDA excluding other income, over revenue) compressed to roughly 26.9% from 29.27% a year ago and 29.25% in Q1 — the squeeze sits on cost of materials and other operating expenses scaling with the API/CDMO ramp-up rather than any single line. Net margin nonetheless expanded to 14.72% from 11.85% YoY, because the effective tax rate fell to 23.5% from 31.6% a year ago under the new tax regime — so this quarter's bottom-line growth leaned more on a lower tax charge than on operating leverage. A ₹0.43 Cr exceptional vendor-legal-settlement charge was also booked but is too small to move the numbers.
The stock went into the print at ₹884.3, down 17.6% over the past month of trading.
For context: revenue is at a 6-quarter high.
No formal numeric guidance. Management visualizes 'healthy and steady growth' with faster profitability trajectory. Expects revenue uplift from Formulation launches (Rotigotine, Abraxane, Enzalutamide, Abiraterone FY28), CDMO commercialization (3 programs FY28), and Biologics launches (Aflibercept FY27, Nivolumab FY28)
— This quarter: met
Management gives no formal numeric guidance; on the August 10, 2026 call it spoke only of "healthy and steady growth" with a "faster profitability trajectory," citing formulation launches (Rotigotine, Abraxane, Enzalutamide, Abiraterone through FY28), three CDMO programs commercialising in FY28, and Biologics launches (Aflibercept FY27, Nivolumab FY28) — this quarter's 43%/80% revenue/PAT growth is broadly consistent with that framing, though there is no numeric bar to grade it against, and no brokerage consensus for this specific quarter surfaced in search. Standalone (parent-only) revenue grew faster YoY (+52.0% to ₹206.14 Cr) than the consolidated figure, while consolidated PAT growth (+79.7%) outpaced standalone (+71.7% to ₹50.12 Cr) — the roughly 9-point revenue gap points to the subsidiary layer (Biologics/CDMO units) growing slower than the parent even as group-level tax efficiency helped the bottom line. The quarter's other notable development: FTF Pharma, a wholly owned subsidiary, was placed under Corporate Insolvency Resolution Process by the NCLT's Ahmedabad bench (order dated September 9, 2026) and was deconsolidated after September 8, 2026, trimming consolidated revenue by ₹2.78 Cr, EBITDA by ₹4.32 Cr and PBT by ₹3.75 Cr for the quarter; management is contesting the order before the NCLAT, which has reserved judgment as of October 8, 2026. No press release accompanied this filing to cross-check against management's own framing.
W1
Biologics launch of Aflibercept targeted for FY27 and Nivolumab for FY28 — management's stated near-term revenue driver to verify in coming quarters
W2
CDMO commercialisation of 3 programs guided for FY28, and formulation launches (Rotigotine, Abraxane, Enzalutamide, Abiraterone) guided through FY28 — track progress against this timeline
W3
NCLAT ruling on FTF Pharma's CIRP challenge (judgment reserved as of Oct 8, 2026) — determines whether the subsidiary returns to consolidation
Record revenue, margin pressure emerging; CDMO momentum solid but execution uncertain
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit H1 revenue/growth targets (44% YoY). PAT strong YoY but QoQ decline (−21.5%) unexplained. Rotigotine delayed 6 months.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong CDMO momentum (150% growth, 25+ NCE programs) and Biologics upside are structural tailwinds. But near-term headwinds from gross margin compression (−700 bps), QoQ profit decline (−21.5%) despite revenue growth (+13.6%), and Rotigotine delay signal execution friction. Management bullish but cautious on forward visibility.
₹538 Cr
Revenue · +43% YoY₹79 Cr
Reported PAT · +79.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Highest ever quarterly revenue
OVERSTATED₹529.1 Cr delivered; CFO claimed ₹538 Cr (+43% YoY actual vs 35% stated)
All 4 engines firing with strong growth
METAPI +24%, Formulation +50%, CDMO +150%, Biologics +150% YoY
Highest ever EBITDA ₹151 Cr, 28% margin
MET₹151 Cr confirmed; margin 28.5% aligns
Gross margins down 700 bps QoQ/YoY
METOPM 26.8%, down from API cost inflation acknowledged
PAT ₹79 Cr for quarter
MET₹79.2 Cr delivered; exact match
Earnings quality
What changed since the last call
Rotigotine launch timing
DowngradeDelayed from FY27 to FY28 H1 (~6 months slip) due to European agency variation approval for raw material.
Biologics strategic elevation
UpgradeNow 12% of revenue (₹65 Cr, +150% YoY), reframed from 'asset under monetization' to 'real business focus'. 7 biosimilars, 2 entering Phase I FY27.
CDMO commercialization pace
Upgrade25+ NCE programs with partners; 4 expected to commercialize in 18–24 months. Japanese programs showing traction.
Margin pressure acknowledged
NeutralAPI raw material cost surge compressed gross margins 700 bps. Management expects recovery when commodity prices normalize; timeline vague.
Capex intensity continues
Neutral₹252 Cr spent H1 on peptide capacity expansion. Expected ~₹500 Cr FY27 (vs ₹456 Cr prior ₹114Cr/quarter guidance). ROCE uplift timing uncertain.
The Q&A
Analysts pressed hard on margin recovery timeline (Parth Mehta), forward guidance (Aryan Mehta), capacity utilization (Gaurav Shukla), segment profitability (Loveleen Bagga). Management held firm on 'no numeric guidance' policy. Answered product/operational questions directly but protected forward visibility. Overall: selective but not evasive.
Gross margin compression — Parth Mehta, Vallum Capital
PartialAPI strong but lower-margin vs formulation. Raw material costs rose; not fully passed to customers. Temporary, expects recovery.
Peptides capex — Manish Bhandari
Answered4 manufacturing lines currently, adding 2 more. Building one of India's largest peptide capacities by end FY27. Space for further expansion.
Peptides utilization — Gaurav Shukla
DodgedDepends on customer uptake. Will give visibility H2 FY27 when confident. Capacities planned based on customer indications.
CDMO order book — Shrikant Akolkar, Nuvama
PartialNo orders in hand yet. Indication from customers based on planned capacity. Will share visibility next year.
Ondansetron launch — Krisha Kansara, The Boring AMC
AnsweredFDA approval pending. Launch expected FY28 H1 after central approval. Marketing partner already tied up.
Specialty CDMO growth FY28 — Aryan Mehta, Shrayas Capital
DodgedCannot give forward guidance. Good growth possible based on program complexity. Partner uptake determines outcome.
New molecule launches — Athul Joby, Prosperity Wealth
PartialDetails in investor presentation segment-wise. Cannot compare Nor-UDCA. Refer to presentation, reach out separately.
Jadcherla plant risk — Amish Kanani
AnsweredNo current revenue risk. Moved critical filings to alternate CMO sites. EU plant cleared again. U.S. business independent of Jadcherla.
Rotigotine delay — Sumit Gupta, Antique
AnsweredDelayed couple quarters for European agency variation approval of raw material. Set to launch FY28 H1.
Service/licensing income — Loveleen Bagga, Systematix
PartialService income has R&D development costs attached. Not 100% margin. Cannot disclose segment proportion.
Guidance
Capex ~₹114 Cr/quarter through FY27 as previously guided
High₹252 Cr H1 spent on peptide/CDMO capacity. On track to commission largest peptide capacity by FY27 end.
Risks the call surfaced
Gross margin recovery
MediumGross margins down 700 bps due to API raw material inflation. Management expects recovery when commodity prices normalize, but no timeline or confidence level given.
QoQ profit decline
MediumQ2 PAT ₹79.2 Cr down 21.5% from implied Q1 ₹100.8 Cr, despite QoQ revenue growth of 13.6%. Not explained on call. Suggests seasonal pattern, one-time Q1 items, or cost control deterioration.
CDMO commercialization
MediumCDMO revenue +150% YoY with 25+ NCE programs in pipeline. 4 expected commercialization in 18–24 months, but detail on ramp/timing lacking. Success depends on partner execution, not solely Shilpa capability.
Product launch delays
LowRotigotine delayed FY27 to FY28 H1 (~6 months) for European agency variation approval. Ondansetron also delayed to FY28 H1. Reduces near-term growth catalysts.
Capex payoff timing
LowHeavy capex cycle (~₹250 Cr per half) to build peptide/CDMO capacity. ROCE at 18.3% adjusted, but normalized return level uncertain. Utilization depends on CDMO customer demand.
Management
Score 7/10. Clear on product roadmap and operational metrics. Deliberately avoids numeric forward guidance ('no formal guidance' policy). Explains margin pressure and cost drivers directly. Transparent on Rotigotine delay. Hit H1 revenue target (44% YoY growth). PAT growth 80% YoY. But QoQ profit decline unexplained; margin compression acknowledged with vague recovery timeline. Rotigotine delayed 6 months. Solid execution with emerging cracks.
1 · FY28 H1
Rotigotine launch in Europe/RoW after regulatory delay
2 · FY28 H1
Ondansetron FDA launch in India markets expected
3 · FY27 Q3–Q4
First CDMO program commercialization (Nivolumab/Aflibercept expected)
Management bullish but cautious on forward visibility.